Eurobio-Scientific SA

  • Market Cap: N/A
  • Industry: Pharmaceuticals & Biotechnology
  • ISIN: FR0013240934
EUR
24.20
-0.35 (-1.43%)
  • Price Points
  • Score
  • Mojo Parameters
  • Total Return
  • News and Corporate Actions
  • Key factors
  • Shareholding
  • Financials
  • CompanyCV
stock-summaryCompany CV
About Eurobio-Scientific SA stock-summary
stock-summary
Eurobio-Scientific SA
Pharmaceuticals & Biotechnology
Eurobio Scientific SA, formerly Diaxonhit, is a France-based biotechnology company engaged in the field of in-vitro diagnostic. It is engaged in activities ranging from discovery to the commercialization of specialty diagnostic products. The Company owns a portfolio of diagnostic products in three specialty areas: infectious diseases; Alzheimer's disease, and cancer. It consists of Tetanos Quick Stick (TQS), which is an unitary test enabling to determine the tetanus vaccination status. It has a portfolio of in-house and co-developed products, including AclarusDx (a blood-based test for the detection of biomarkers specific for Alzheimer's disease). The portfolio includes BJI Inoplex for prosthetic infections and EHT Dx14 for breast cancer (both in validation phase). The co-developed products include research programs for the identification of predictive biomarkers of response for anti-HER2 and anti-angiogenic therapies, among others. It operates through Genbio and Eurobio Capforce Plus.
Company Coordinates stock-summary
Company Details
Les Ulis Cedex , LES ULIS None : 91953
stock-summary
Tel: 33 1 5394770033 1 53945249
stock-summary
Registrar Details
stock-recommendation Shareholding
Shareholding Snapshotstock-summary
Icon
No data for shareholding present.
Shareholding Compare (%holding) stock-summary
Icon
No data for shareholding present.
stock-summary Board of Directorsstock-summary
Management
Designation
Mr. Laurent Condomine
Chairman of the Supervisory Board
Mr. Jean-Pierre Hermet
Vice Chairman of the Supervisory Board
Mr. Christophe Jean
Member of the Supervisory Board
Mr. Michel Picot
Member of the Supervisory Board
stock-recommendation Stock DNA
Revenue and Profits:
Net Sales:
(Quarterly Results - )
Net Profit:
stock-summary
Industry

Pharmaceuticals & Biotechnology

stock-summary
Market cap

EUR 249 Million ()

stock-summary
P/E

43.00

stock-summary
Industry P/E

NA

stock-summary
Dividend Yield

0.00%

stock-summary
Debt Equity

-0.07

stock-summary
Return on Equity

3.30%

stock-summary
Price to Book

1.37